A Novel Heterologous Prime-boost Strategy Using RUTI Vaccine to Improve the Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer Patients: Phase 1 RUTIVAC-1 Trial.


Por: Buisan O, Servian P, Pedreño-Lopez S, Pagès J, Urrea V, Martínez R, Garcia E, Cardona PJ, Vilaplana C, Amat M, Areal J, Bellmunt J, Clotet B and Cabrera C

Publicada: 1 feb 2026 Ahead of Print: 14 oct 2025
Resumen:
Intravesical bacillus Calmette-Guérin (BCG) is the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC); however, recurrence and progression remain major challenges. To explore a heterologous prime-boost strategy, we conducted the RUTIVAC-1 trial (NCT03191578) to evaluate RUTI, a nonlive vaccine, derived from Mycobacterium tuberculosis, as a systemic primer prior to intravesical BCG in high-risk NMIBC patients. The immunogenicity, safety, and preliminary efficacy of RUTI was evaluated. In this phase 1, randomized, double-blind, placebo-controlled trial, 40 NMIBC patients were randomized 1:1 to receive two subcutaneous doses of RUTI (25 µg) or placebo before BCG treatment. Immunogenicity was assessed by flow cytometry, and clinical follow-up was extended to 5 yr. RUTI induced a systemic vaccine-specific response, increasing activation markers on CD4(+) and CD8(+) T cells, supporting effective immune priming. Regulatory T-cell expansion was observed in the placebo group but not in RUTI-vaccinated patients, who also exhibited a more heterogeneous and polyfunctional specific immune response. RUTI was safe and well tolerated, with only mild injection-site reactions. Exploratory analyses showed a trend toward reduced recurrence, progression, and death, with improved 5-yr progression-free survival. The small sample size and baseline imbalances were the limitations. This phase 1 study supports the safety and immunogenicity of RUTI and provides encouraging data that warrant confirmation in larger trials to establish its potential clinical benefit as a novel therapeutic strategy.

Filiaciones:
Buisan O:
 Department of Urology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

 Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain

:
 Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain

Pedreño-Lopez S:
 IrsiCaixa, Badalona, Barcelona, Spain

:
 Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain

:
 IrsiCaixa, Badalona, Barcelona, Spain

Martínez R:
 Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain

 Department of Urology, Hospital Universitario Río Hortega, Valladolid, Spain

:
 IrsiCaixa, Badalona, Barcelona, Spain

:
 Microbiology Department, Northern Metropolitan Clinical Laboratory, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

 Unitat de Tuberculosi Experimental, Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Catalonia, Spain

 Autonomous University of Barcelona, Bellaterra, Spain

:
 Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain

 Autonomous University of Barcelona, Bellaterra, Spain

 CIBER Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid, Spain

 High-Complexity Transversal Area in Tuberculosis, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

Amat M:
 Archivel Farma, Badalona, Barcelona, Spain

Areal J:
 Department of Urology, IDIBELL, Hospital Universitario de Bellvitge, Barcelona, Spain

Bellmunt J:
 Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

:
 IrsiCaixa, Badalona, Barcelona, Spain

 Infectious Diseases Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

 Universitat de Vic Central de Catalunya, Vic, Spain

:
 IrsiCaixa, Badalona, Barcelona, Spain

 Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain

 Autonomous University of Barcelona, Bellaterra, Spain
ISSN: 03022838





European Urology
Editorial
Elsevier BV, RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Países Bajos
Tipo de documento: Article
Volumen: 89 Número: 2
Páginas: 114-120
WOS Id: 001682578600001
ID de PubMed: 41084757
imagen Green Submitted

MÉTRICAS